Immuron Reports Record First-Half Sales of Travelan, Expands Product Line in Australia
Immuron (NASDAQ:IMRN) reported record first-half sales for Travelan®, achieving a 5% year-over-year increase in global revenue to AUD$4.2 million, with significant contributions from Australia and the U.S. The company also launched ProIBS®, a medical device for irritable bowel syndrome, in Australia and is preparing for further commercial expansion while awaiting clinical results for its military-grade diarrhea prevention treatments funded by the U.S. Department of Defense.
Theia Market Signal Identification - AI Assisted
Immuron (NASDAQ:IMRN) reported record first-half sales for Travelan®, with a 5% year-over-year increase in global revenue to AUD$4.2 million. Australia contributed AUD$3.3 million, a 13% rise from the previous year.
U.S. sales surged 17% to AUD$0.9 million due to enhanced social media promotions and new Amazon listings. Canadian sales declined 85% due to inventory issues but rebounded with a 191% increase in the second quarter.
The company launched ProIBS®, a medical device for irritable bowel syndrome, in Australia and secured listings with major pharmacy wholesalers. Immuron is positioned to support its commercial expansion and clinical development strategies, awaiting key clinical results for its military-grade diarrhea prevention treatments, funded by the U.S. Department of Defense.
Comments